Department of Pharmaceutical Sciences and Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198-5830, USA.
J Control Release. 2013 Dec 10;172(2):589-600. doi: 10.1016/j.jconrel.2013.04.010. Epub 2013 Apr 25.
Cancer treatment that uses a combination of approaches with the ability to affect multiple disease pathways has been proven highly effective in the treatment of many cancers. Combination therapy can include multiple chemotherapeutics or combinations of chemotherapeutics with other treatment modalities like surgery or radiation. However, despite the widespread clinical use of combination therapies, relatively little attention has been given to the potential of modern nanocarrier delivery methods, like liposomes, micelles, and nanoparticles, to enhance the efficacy of combination treatments. This lack of knowledge is particularly notable in the limited success of vectors for the delivery of combinations of nucleic acids with traditional small molecule drugs. The delivery of drug-nucleic acid combinations is particularly challenging due to differences in the physicochemical properties of the two types of agents. This review discusses recent advances in the development of delivery methods using combinations of small molecule drugs and nucleic acid therapeutics to treat cancer. This review primarily focuses on the rationale used for selecting appropriate drug-nucleic acid combinations as well as progress in the development of nanocarriers suitable for simultaneous delivery of drug-nucleic acid combinations.
癌症治疗采用多种方法结合，能够影响多种疾病途径，已被证明对多种癌症的治疗非常有效。联合治疗可以包括多种化疗药物或化疗药物与手术或放疗等其他治疗方式的组合。然而，尽管联合治疗在临床上广泛应用，但人们对现代纳米载体传递方法（如脂质体、胶束和纳米颗粒）增强联合治疗效果的潜力关注甚少。这种知识的缺乏在用于传递核酸与传统小分子药物组合的载体的有限成功中尤为明显。由于两种类型的药物在理化性质上存在差异，因此药物-核酸组合的传递尤其具有挑战性。本文综述了使用小分子药物和核酸治疗药物联合治疗癌症的递药方法的最新进展。本文主要侧重于选择合适的药物-核酸组合的基本原理，以及开发适合同时递药-核酸组合的纳米载体的进展。
